Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Non-Current Debt (2021)

Historic Non-Current Debt for Supernus Pharmaceuticals (SUPN) over the last 4 years, with Q4 2021 value amounting to $379.3 million.

Supernus Pharmaceuticals' Non-Current Debt changed N/A to $379.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $379.3 million, marking a year-over-year change of. This contributed to the annual value of $379.3 million for FY2021, which is N/A changed from last year.
According to the latest figures from Q4 2021, Supernus Pharmaceuticals' Non-Current Debt is $379.3 million.
Supernus Pharmaceuticals' 5-year Non-Current Debt high stood at $379.3 million for Q4 2021, and its period low was $379.3 million during Q4 2021.